Format

Send to

Choose Destination
Br J Psychiatry Suppl. 2004 Apr;47:S94-101.

Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications.

Author information

1
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA. p_cavazzoni@lilly.com

Erratum in

  • Br J Psychiatry Suppl. 2005 May;186:449.

Abstract

AIMS:

In this retrospective analysis, we assessed the short-term risk of treatment-emergent diabetes (TED) among patients with schizophrenia during clinical trials of antipsychotic medications.

METHOD:

From a non-diabetic cohort of patients with schizophrenia (n=5013), the relationship between baseline non-fasting glucose measurement, presence at baseline of risk factors for diabetes, weight gain and therapy assignment on the risk of treatment-emergent diabetes were assessed.

RESULTS:

At the baseline assessment, about a third of patients identified with TED during treatment had non-fasting glucose levels over 7.8 mmol/l and two-thirds had multiple diabetes risk factors. Both baseline non-fasting glucose level and the presence of multiple pre-existing diabetes risk factors appeared to have a major impact on the risk of developing diabetes.

CONCLUSIONS:

Overall, risk factors for diabetes in patients with schizophrenia overlap those in the general population. The results also suggest that many patients identified with TED might have had pre-existing glycaemic abnormalities or a high baseline burden of diabetes risk factors.

PMID:
15056601
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center